Product image of Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor) supplied by GNH India

Haemate P

Active Ingredient:
Human Coagulation Factor Viii, Human Von Willebrand Factor
Origin:
EU

Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is a prescription injectable solution containing human coagulation factor VIII and von Willebrand factor. It is supplied as a sterile intravenous preparation used to replace deficient clotting proteins in patients with bleeding disorders. The product is manufactured for the European market and is classified as a coagulation factor concentrate. Haemate P is administered under medical supervision to support normal clot formation and platelet adhesion.

Manufacturer / TM Owner

Csl Behring S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Haemate P is indicated for the management of several inherited bleeding disorders where factor VIII and von Willebrand factor are deficient or dysfunctional.

  • Treatment of acute bleeding episodes in patients with hemophilia A.
  • Routine prophylaxis to prevent spontaneous bleeds in hemophilia A.
  • Management of von Willebrand disease types 1, 2, and 3, including on‑demand therapy for bleeding.
  • Surgical or invasive procedure support to maintain hemostasis in affected individuals.
  • Use in combination with other hemostatic agents when clinically appropriate.

Side Effects

Adverse reactions reported with Haemate P vary in frequency and severity.

Common

  • Injection site pain or erythema.
  • Headache.
  • Fever or chills.
  • Nausea or vomiting.
  • Transient increase in liver enzymes.

Serious

  • Development of inhibitors (antibodies) to factor VIII.
  • Anaphylactic or severe allergic reactions.
  • Thromboembolic events.
  • Hemolysis.
  • Disseminated intravascular coagulation (DIC).

Precautions & Warnings

Before initiating Haemate P therapy, clinicians should evaluate several safety considerations.

  • Assess patient history for previous inhibitors to factor VIII.
  • Monitor for signs of allergic reactions during and after infusion.
  • Evaluate liver and renal function prior to treatment.
  • Use caution in patients with a history of thrombosis or cardiovascular disease.
  • Adjust dose in pediatric patients and those with low body weight.
  • Avoid use in individuals with known hypersensitivity to any component of the product.
  • Ensure proper storage and handling to maintain product stability.

Avoid Interactions

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid

  • Concurrent use of other factor concentrates without medical supervision.
  • High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.
  • Antifibrinolytic agents unless specifically indicated.

Use with caution

  • Immunosuppressive therapies that may alter inhibitor development.
  • Warfarin or other anticoagulants; monitor coagulation parameters closely.
  • Desmopressin (DDAVP) when combined with Haemate P for von Willebrand disease.

Frequently Asked Questions

Haemate P contains human coagulation factor VIII and human von Willebrand factor as its active ingredients.

Haemate P is given as an intravenous injection under the supervision of a healthcare professional.

Haemate P is used for hemophilia A and von Willebrand disease types 1, 2, and 3.

Yes, Haemate P may be administered before surgery or invasive procedures to help maintain hemostasis in patients with factor deficiencies.

Common side effects include injection site pain, headache, fever or chills, nausea, and temporary elevation of liver enzymes.

Serious reactions can include development of factor VIII inhibitors, severe allergic responses, thromboembolic events, hemolysis, and disseminated intravascular coagulation.

Yes, a history of inhibitors to factor VIII should be evaluated, and testing may be performed before initiating therapy.

Concurrent use of other factor concentrates should be avoided unless specifically directed by a physician.

Haemate P combines both factor VIII and von Willebrand factor in a single preparation, providing dual activity for patients who need both proteins.

Patients should be observed for signs of allergic reactions, and coagulation parameters may be checked to assess treatment effectiveness.

Haemate P may be used in pediatric patients, but dosing adjustments and careful monitoring are required.

Haemate P should be stored according to the manufacturer’s instructions, typically refrigerated and protected from light until use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Coagulation Factor Viii, Human Von Willebrand Factor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT